Premium
Vitamin C and B 3 as new biomaterials to alter intestinal stem cells
Author(s) -
Qi Yijun,
Lohman Jo,
Bratlie Kaitlin M.,
PeroutkaBigus Nathan,
Bellaire Bryan,
Wannemuehler Michael,
Yoon KyoungJin,
Barrett Terrence A.,
Wang Qun
Publication year - 2019
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.36715
Subject(s) - vitamin , stem cell , ascorbic acid , vitamin c , vitamin d and neurology , biology , gut flora , homeostasis , medicine , endocrinology , biochemistry , microbiology and biotechnology , food science
Vitamin C (ascorbic acid) and vitamin B 3 (niacin) have been extensively studied since the 20th century. In the area of stem cell biology, vitamin C has shown its direct impact toward homeostasis and epigenetic changes (D'Aniello et al., Stem Cells International, 2017, 1–16). Vitamin B 3 aids in maintaining healthy intestinal homeostasis and reducing gut inflammation by participating in the rapamycin signaling pathway (Kumar et al., The American Journal of Physiology‐Gastrointestinal and Liver Physiology, 2013). In this study, vitamin C and vitamin B 3 (600 and 1,200 μg/mL) have been explored as potential new biomaterials to study their effects on four types of intestinal stem cells which are isolated from mice bearing different microbiota. We observed that C3H ASF and 129 ASF IL‐10 are more sensitive towardB7 600 μg/mL vitamin B 3 and 1,200 μg/mL vitamin C. The lowest growth rate and viability for all types of organoids was with 1,200 μg/mL vitamin C. From quantitative polymerase chain reaction analysis (qPCR analysis), MUC2 was upregulated for 129 ASF and C3H Conv when exposed to 600 μg/mL and 1,200 μg/mL vitamin C. It suggests that large amounts of glycoprotein may be produced after adding high concentrations of vitamin C. Since inflammatory bowel disease has low level of MUC2, this finding may be helpful in restoring mucosal health by upregulating the MUC2 gene while altering patient's microbiota (Sibila et al., Annals of the American Thoracic Society, 2016). These results are expected to have a positive translational impact because this bottom‐up strategy would be instrumental in developing Vitamin C and B3 based orally available therapeutic strategies and formula for advancing the fields of gastrointestinal regenerative medicine.